Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Symbicort TBH- Turbuhaler · 1 trial · 1 indication
Time to severe exacerbation among patients
| Arm | Type | Description |
|---|---|---|
| Symbicort | EXPERIMENTAL | Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed) |
| Conventional BP | EXPERIMENTAL | Conventional Best Practice for Treatment of Asthma |
| Name | Type | Description |
|---|---|---|
| Symbicort TBH - Turbuhaler | DRUG | Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed) |
| beta-II-agonist, inhale steroid | DRUG | Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage |
Inclusion Criteria: * Signed informed consent form. If the patient cannot read and write, verbal consent from the patient is required. * Ability to read and write in Turkish * Female or male outpatients aged 18 years * Minimum of 3 months history of asthma, diagnosed according to the American Thora...
Symbicort TBH-Turbuhaler is used for the treatment of persistent asthma in adults. It is a small molecule respiratory therapy developed by AstraZeneca PLC. The drug is administered via a Turbuhaler device and is intended for patients aged 18 years and older.
Symbicort TBH-Turbuhaler is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is responsible for the research, development, and commercialization of this asthma treatment.
Symbicort TBH-Turbuhaler is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under evaluation for the treatment of persistent asthma.
Symbicort TBH-Turbuhaler has one completed Phase 3 clinical trial, identified by the NCT number NCT00628758. The trial, titled 'A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma,' enrolled 430 participants in Turkey and was a randomized, controlled study.
Symbicort TBH-Turbuhaler is a specific formulation of Symbicort, delivered via a Turbuhaler device. The drug is developed by AstraZeneca and is being studied for asthma. The trial NCT00628758 compares this single inhaler therapy with conventional best practice for persistent asthma.